939 related articles for article (PubMed ID: 33357452)
1. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Srivastava S; Furlan SN; Jaeger-Ruckstuhl CA; Sarvothama M; Berger C; Smythe KS; Garrison SM; Specht JM; Lee SM; Amezquita RA; Voillet V; Muhunthan V; Yechan-Gunja S; Pillai SPS; Rader C; Houghton AM; Pierce RH; Gottardo R; Maloney DG; Riddell SR
Cancer Cell; 2021 Feb; 39(2):193-208.e10. PubMed ID: 33357452
[TBL] [Abstract][Full Text] [Related]
2. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.
Wallstabe L; Göttlich C; Nelke LC; Kühnemundt J; Schwarz T; Nerreter T; Einsele H; Walles H; Dandekar G; Nietzer SL; Hudecek M
JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31415244
[TBL] [Abstract][Full Text] [Related]
3. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
4.
Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
[TBL] [Abstract][Full Text] [Related]
5. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
[TBL] [Abstract][Full Text] [Related]
6. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.
Srivastava S; Salter AI; Liggitt D; Yechan-Gunja S; Sarvothama M; Cooper K; Smythe KS; Dudakov JA; Pierce RH; Rader C; Riddell SR
Cancer Cell; 2019 Mar; 35(3):489-503.e8. PubMed ID: 30889382
[TBL] [Abstract][Full Text] [Related]
7. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
8. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
[TBL] [Abstract][Full Text] [Related]
9. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
11. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
12. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
13. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.
Berger C; Sommermeyer D; Hudecek M; Berger M; Balakrishnan A; Paszkiewicz PJ; Kosasih PL; Rader C; Riddell SR
Cancer Immunol Res; 2015 Feb; 3(2):206-16. PubMed ID: 25355068
[TBL] [Abstract][Full Text] [Related]
14. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
15. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
Huang X; Park H; Greene J; Pao J; Mulvey E; Zhou SX; Albert CM; Moy F; Sachdev D; Yee D; Rader C; Hamby CV; Loeb DM; Cairo MS; Zhou X
PLoS One; 2015; 10(7):e0133152. PubMed ID: 26173023
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
19. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
